Review
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jan 15, 2024; 16(1): 13-29
Published online Jan 15, 2024. doi: 10.4251/wjgo.v16.i1.13
New trends in diagnosis and management of gallbladder carcinoma
Efstathios T Pavlidis, Ioannis N Galanis, Theodoros E Pavlidis
Efstathios T Pavlidis, Ioannis N Galanis, Theodoros E Pavlidis, 2nd Propedeutic Department of Surgery, Hippokration General Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki 54642, Greece
Author contributions: Pavlidis TE designed research, contributed new analytic tools, analyzed data and review; Galanis IN analyzed data and review; Pavlidis ET performed research, analyzed data, review, and wrote the paper.
Conflict-of-interest statement: There is no conflict of interest associated with the senior author or any of the other coauthors who contributed their efforts in this manuscript.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Theodoros E Pavlidis, Doctor, PhD, Emeritus Professor, Surgeon, 2nd Propedeutic Department of Surgery, Hippokration General Hospital, School of Medicine, Aristotle University of Thessaloniki, Konstantinoupoleos 49, Thessaloniki 54642, Greece. pavlidth@auth.gr
Received: November 11, 2023
Peer-review started: November 11, 2023
First decision: December 6, 2023
Revised: December 6, 2023
Accepted: December 19, 2023
Article in press: December 19, 2023
Published online: January 15, 2024
Core Tip

Core Tip: Gallbladder (GB) carcinoma is a rare but aggressive malignancy with a poor prognosis. Therapeutic surgical resection constitutes the only chance of cure, but only in earlier stages. For advanced-stage patients, multimodality treatment is necessary. Early and accurate preoperative evaluation is essential for the best choice of surgical management, determining the correct extent of resection and the type of novel adjuvant or neoadjuvant treatment. Application of targeted treatment and immunotherapy has broadened the management armamentarium for GB carcinomas, but future work must focus on increasing efficiency. The most extended operative procedures remain under debate. An individualized approach may be more suitable.